The Interpretation of Serum Prostate Specific Antigen in Men Receiving 5α-Reductase Inhibitors: A Review and Clinical Recommendations

Journal of Urology

Volumn 176, Issue 3, 2006, Pages 868-874

  Marks, Leonard S ^a   Andriole, Gerald L ^b   Fitzpatrick, John M ^c   Schulman, Claude C ^d   Roehrborn, Claus G ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

prostate; prostate specific antigen; prostatic neoplasms; testosterone 5 alpha reductase

Indexed keywords

DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER INCIDENCE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFECT; ENZYME INHIBITION; HISTOLOGY; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

CHOLESTENONE 5 ALPHA-REDUCTASE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33746543255     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.04.024     Document Type: Review

References (48)

1. Quinn M., and Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90 (2002) 162
2. Cancer Facts and Figures (2003), American Cancer Society, Atlanta
3. Sarma A.V., and Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States. 1981-2001. Semin Urol Oncol 20 (2002) 3
4. Carter H.B. Prostate cancers in men with low PSA levels-must we find them. N Engl J Med 350 (2004) 2292
5. Lieberman R. Evidence-based medical perspectives. the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 11 (2004) 501
6. Prostate Cancer Early Detection (2004) National Comprehensive Cancer Network, Version 1
7. Chu K.C., Tarone R.E., and Freeman H.P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97 (2003) 1507
8. Bartsch G., Horninger W., Klocker H., Reissigl A., Oberaigner W., Schonitzer D., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417
9. Feuer E.J., Mariotto A., and Merrill R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer 95 (2002) 870
10. Labrie F., Candas B., Dupont A., Cusan L., Gomez J.L., Suburu R.E., et al. Screening decreases prostate cancer death. first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 (1999) 83
11. Bruchovsky N., Rennie P.S., Batzold F.H., Goldenberg S.L., Fletcher T., and McLoughlin M.G. Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J Clin Endocrinol Metab 67 (1988) 806
12. Geller J., Albert J., Loza D., Geller S., Stoeltzing W., and de la Vega D. DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 46 (1978) 440
13. Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289
14. Roddam A.W., Duffy M.J., Hamdy F.C., Ward A.M., Patnick J., Price C.P., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml. systematic review and meta-analysis. Eur Urol 48 (2005) 386
15. Magklara A., Scorilas A., Stephan C., Kristiansen G.O., Hauptmann S., Jung K., et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56 (2000) 527
16. Bartsch G., Fitzpatrick J., Schalken J., Isaacs J.T., Nordling J., and Roehrborn C.G. Consensus statement. the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 93 suppl (2004) 27
17. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer. results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283
18. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
19. Babaian R.J., Johnston D.A., Naccarato W., Ayala A., Bhadkamkar V.A., and Fritsche Jr. H.H. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml. relation to biopsy strategy. J Urol 165 (2001) 757
20. Krumholtz J.S., Carvalhal G.F., Ramos C.G., Smith D.S., Thorson P., Yan Y., et al. Prostate-specific antigen cutoff of 26 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60 (2002) 469
21. Catalona W.J., Smith D.S., Ratliff T.L., and Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948
22. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer. what happened in the last 20 years?. J Urol 172 (2004) 1297
23. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215
24. Raaijmakers R., Blijenberg B.G., Finlay J.A., Rittenhouse H.G., Wildhagen M.F., Roobol M.J., et al. Prostate cancer detection in the prostate specific antigen range of 20 to 3.9 ng/ml. value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 171 (2004) 2245
25. Raaijmakers R., Wildhagen M.F., Ito K., Paez A., de Vries S.H., Roobol M.J., et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63 (2004) 316
26. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
27. Ornstein D.K., Smith D.S., Rao G.S., Basler J.W., Ratliff T.L., and Catalona W.J. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 157 (1997) 2179
28. Eastham J.A., Riedel E., Scardino P.T., Shike M., Fleisher M., Schatzkin A., et al. Variation of serum prostate-specific antigen levels. an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695
29. Span P.N., Voller M.C., Smals A.G., Sweep F.G., Schalken J.A., Feneley M.R., et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 161 (1999) 332
30. Guess H.A., Gormley G.J., Stoner E., and Oesterling J.E. The effect of finasteride on prostate specific antigen. review of available data. J Urol 155 (1996) 3
31. Guess H.A., Heyse J.F., Gormley G.J., Stoner E., and Oesterling J.E. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 20 (1993) 627
32. Oesterling J.E., Roy J., Agha A., Shown T., Krarup T., Johansen T., et al., The Finasteride PSA Study Group. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer. effects of finasteride. Urology 50 (1997) 13
33. Andriole G.L., Guess H.A., Epstein J.I., Wise H., Kadmon D., Crawford E.D., et al., PLESS Study Group. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Proscar Long-Term Efficacy and Safety Study. Urology 52 (1998) 195
34. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.L., Miller G.J., Ford L.G., et al. The influence of finasteride On the development of prostate cancer. N Engl J Med 349 (2003) 215
35. Bramson H.N., Hermann D., Batchelor K.W., Lee F.W., James M.K., and Frye S.V. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 282 (1997) 1496
36. Clark R.V., Hermann D.J., Gabriel H., Wilson T.H., Morrill B.B., and Hobbs S. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel, dual 5 alpha reductase inhibitor. J Urol 161 suppl (1999) 268 abstract 1037
37. Andriole G., Marberger M., and Roehrborn C.G. Clinical usefulness of serum prostate specific antigen in the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 175 (2006) 1657
38. Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., et al., The Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327 (1992) 1185
39. Guess H.A., Heyse J.F., and Gormley G.J. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 22 (1993) 31
40. Punglia R.S., D'Amico A.V., Catalona W.J., Roehl K.A., and Kuntz K.M. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349 (2003) 335
41. Etzioni R.D., Howlader N., Shaw P.A., Ankerst D.P., Penson D.F., Goodman P.J., et al. Long-term effects of finasteride on prostate specific antigen levels. results from the prostate cancer prevention trial. J Urol 174 (2005) 877
42. Kaplan S.A., Ghafar M.A., Volpe M.A., Lam J.S., Fromer D., and Te A.E. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy. preliminary study. Urology 60 (2002) 464
43. Remzi M., Djavan B., Wammack R., Momeni M., Seitz C., Erne B., et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy?. Urology 61 (2003) 161
44. Basillote J.B., Armenakas N.A., Hochberg D.A., and Fracchia J.A. Influence of prostate volume in the detection of prostate cancer. Urology 61 (2003) 167
45. McConnell J.D., Bruskewitz R., Walsh P.C., Andriole G., Lieber M.M., Holtgrewe H.L., et al., Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557
46. Debruyne F., Barkin J., van Erps P., Reis M., Tammela T.L., Roehrborn C., et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488
47. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434
48. Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., et al. Chemoprevention of prostate cancer in men at high risk. rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314